Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results suggest that TREK-1 could be a potential therapeutic target for treatment of bipolar disorders as well as depression, while TREK-2 is a target well suited for treatment of major depression.
|
29156592 |
2017 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
This 17-amino acid peptide blocks TREK-1 channels, an original target in depression.
|
30291907 |
2019 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
The TREK-1 channel represents a crucial target in the pathogenesis of stroke and depression.
|
31325429 |
2019 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest that TREK-1 plays an active role in depression, pain and neuroprotection.
|
28192611 |
2017 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent in vivo studies have demonstrated that TREK1, the most thoroughly studied K(2P) channel, has a key role in the cellular mechanisms of neuroprotection, anaesthesia, pain and depression.
|
17375039 |
2007 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
The TWIK-related K<sup>+</sup> channel-1 (TREK-1) controls several major cellular responses involved in memory formation and is believed to participate in the development of depression, cerebral ischemia and blood-brain barrier dysfunction.
|
29042297 |
2017 |
Depressive disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we investigated the effects of the TREK1 ion channel inhibitor anandamide and the TRPC3/6 inhibitor norgestimate on microRNA expression and antidepressant effect in the mouse chronic mild stress (CMS) model of depression.
|
28716528 |
2017 |
Depressive disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, sortilin physically interacts with the two pore domain potassium channel TREK-1 and the PE as well as its synthetic analog spadin is able to block the activation of TREK-1 highlighting their role in the depression pathology.
|
30670975 |
2018 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, the two-pore domain potassium channel TREK-1 has been identified as a new target in depression, and its antagonists might become effective antidepressants.
|
20405001 |
2010 |
Depressive disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrate that the TREK-1 expression and function are altered in the absence of sortilin confirming the importance of this channel in the regulation on the mood as a crucial target to treat depression.
|
30127743 |
2018 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the nervous system, TREK-1 is involved in many physiological and pathological processes such as depression, neuroprotection, pain, and anesthesia.
|
31031627 |
2019 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
To study the role of hippocampal neuronal TREK-1 in a lipopolysaccharide (LPS)-induced depression model, we injected AAV-hSyn-BFP (nCTL group) or AAV-hSyn-BFP-Cre (nCre group) virus into the hippocampus of Cd-TREK-1 KD mice.
|
31771312 |
2019 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
TREK-1, a two-pore-domain potassium channel, has been implicated in the pathogenesis of stroke and depression.
|
25675906 |
2015 |
Depressive disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The mammalian K2P2.1 potassium channel (TREK-1, KCNK2) is highly expressed in excitable tissues, where it plays a key role in the cellular mechanisms of neuroprotection, anesthesia, pain perception, and depression.
|
18474599 |
2008 |
Depressive disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pharmacologically reversible mutations of TREK channels will help to clarify the importance of these channels in pathophysiological conditions such as pain and depression.
|
31455781 |
2019 |
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
This 17-amino acid peptide blocks TREK-1 channels, an original target in depression.
|
30291907 |
2019 |
Mental Depression
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrate that the TREK-1 expression and function are altered in the absence of sortilin confirming the importance of this channel in the regulation on the mood as a crucial target to treat depression.
|
30127743 |
2018 |
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
To study the role of hippocampal neuronal TREK-1 in a lipopolysaccharide (LPS)-induced depression model, we injected AAV-hSyn-BFP (nCTL group) or AAV-hSyn-BFP-Cre (nCre group) virus into the hippocampus of Cd-TREK-1 KD mice.
|
31771312 |
2019 |
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
TREK-1, a two-pore-domain potassium channel, has been implicated in the pathogenesis of stroke and depression.
|
25675906 |
2015 |
Mental Depression
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we investigated the effects of the TREK1 ion channel inhibitor anandamide and the TRPC3/6 inhibitor norgestimate on microRNA expression and antidepressant effect in the mouse chronic mild stress (CMS) model of depression.
|
28716528 |
2017 |
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TWIK-related K<sup>+</sup> channel-1 (TREK-1) controls several major cellular responses involved in memory formation and is believed to participate in the development of depression, cerebral ischemia and blood-brain barrier dysfunction.
|
29042297 |
2017 |
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the nervous system, TREK-1 is involved in many physiological and pathological processes such as depression, neuroprotection, pain, and anesthesia.
|
31031627 |
2019 |
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, the two-pore domain potassium channel TREK-1 has been identified as a new target in depression, and its antagonists might become effective antidepressants.
|
20405001 |
2010 |
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that TREK-1 could be a potential therapeutic target for treatment of bipolar disorders as well as depression, while TREK-2 is a target well suited for treatment of major depression.
|
29156592 |
2017 |
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Pharmacologically reversible mutations of TREK channels will help to clarify the importance of these channels in pathophysiological conditions such as pain and depression.
|
31455781 |
2019 |